Targeting PCSK9 for the treatment of hypercholesterolemia

Current Opinion in Investigational Drugs

Volumn 10, Issue 9, 2009, Pages 938-946

  Hedrick, J A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cholesterol; Dyslipidemia; Hepatocyte; LDL receptor; PCSK9

Indexed keywords

BERBERINE; FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROTEIN PCSK9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG STRUCTURE; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; LIVER; NONHUMAN; PROTEIN TARGETING; REVIEW; VALIDITY;

ANIMALS; CATALYTIC DOMAIN; CHOLESTEROL; CHOLESTEROL, LDL; HYPERCHOLESTEROLEMIA; LIVER; MICE; MUTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, LDL; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS;

EID: 69549101648     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA (2003) 100(3):928-933. (Pubitemid 36183932)
2. Abifadel M, Varret M, Rabés JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A et al: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet (2003) 34(2):154-156. •• Landmark study identifying mutations in PCSK9 as the third known cause of familial hypercholesterolemia. (Pubitemid 36666925)
3. Maxwell KN, Breslow JL: Adenoviral-mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA (2004) 101(18): 7100-7105.
4. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, Trillard M et al: NARC-1/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem (2004) 279(47):48865-48875. (Pubitemid 39625767)
5. Park SW, Moon YA, Horton JD: Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem (2004) 279(48):50630-50638.
6. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD: Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci USA (2005) 102(15):5374-5379. (Pubitemid 40530265)
7. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet (2005) 37(2):161-165. • Along with reference [8], demonstrates that mutations in PCSK9 are associated with low serum cholesterol. (Pubitemid 41716264)
8. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 354(12): 1264-1272. • Correlates PCSK9 to low serum cholesterol and reductions in the incidence of heart disease.
9. Kathiresan S: A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. N Engl J Med (2008) 358(21):2299-2300. (Pubitemid 351724483)
10. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, Naoumova R, Thompson GR, Seed M, Durrington PN, Miller JP et al: Genetic causes of familial hypercholesterolaemia in patients in the UK: Relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 43(12):943-949. (Pubitemid 46080192)
11. Folsom AR, Peacock JM, Boerwinkle E: Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence. Cancer Epidemiol Biomarkers Prev (2007) 16(11):2455-2458.
12. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH: Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet (2006) 79(3): 514-523. (Pubitemid 44384260)
13. 679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis (2007) 193(2):445-448.
14. Abifadel M, Rabés JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C: Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat (2009) 30(4):520-529.
15. Seidah NG: PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets (2009) 13(1):19-28.
16. Lambert G, Charlton F, Rye KA, Piper DE: Molecular basis of PCSK9 function. Atherosclerosis (2009) 203(1):1-7.
17. Costet P, Krempf M, Cariou B: PCSK9 and LDL cholesterol: Unravelling the target to design the bullet. Trends Biochem Sci (2008) 33(9):426-434.
18. Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP: The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol. Structure (2007) 15(5):545-552. (Pubitemid 46702689)
19. Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA, Spraggon G: The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci USA (2007) 104(37): 14604-14609. (Pubitemid 350003191)
20. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR, Mansour MN et al: Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol (2007) 14(5):413-419. (Pubitemid 46685885)
21. Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J: Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA (2008) 105(6):1820-1825. •• Reveals structural details of the PCSK9-LDLR interaction.
22. McNutt MC, Lagace TA, Horton JD: Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem (2007) 282(29):20799-20803. • Along with reference [23], provides the first definitive evidence that PCSK9 does not directly degrade LDLR via enzymatic activity.
23. Li J, Tumanut C, Gavigan JA, Huang WJ, Hampton EN, Tumanut R, Suen KF, Trauger JW, Spraggon G, Lesley SA, Liau G et al: Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J (2007) 406(2):203-207. • Along with reference [22], provides definitive evidence that PCSK9 does not directly degrade LDLR via enzymatic activity. (Pubitemid 47310950)
24. Cameron J, Holla OL, Laerdahl JK, Kulseth MA, Ranheim T, Rognes T, Berge KE, Leren TP: Characterization of novel mutations in the catalytic domain of the PCSK9 gene. J Intern Med (2008) 263(4):420-431. (Pubitemid 351342682)
25. Cameron J, Holla ØL, Ranheim T, Kulseth MA, Berge KE, Leren TP: Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet (2006) 15(9):1551-1558.
26. Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG: The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: Functional consequences of natural mutations and post-translational modifications. J Biol Chem (2006) 281(41):30561-30572. (Pubitemid 44582112)
27. Homer VM, Marais AD, Charlton F, Laurie AD, Hurndell N, Scott R, Mangili F, Sullivan DR, Barter PJ, Rye KA, George PM et al: Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis (2008) 196(2):659-666.
28. Maxwell KN, Fisher EA, Breslow JL: Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA (2005) 102(6):2069-2074.
29. Goldstein JL, Anderson RG, Brown MS: Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature (1979) 279(5715):679-685.
30. Anderson RG, Brown MS, Goldstein JL: Role of the coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblasts. Cell (1977) 10(3): 351-364.
31. 125I-LDL in normal and mutant human fibroblasts. A quantitative autoradiographic study. Exp Cell Res (1979) 121(1):135-142.
32. Rudenko G, Henry L, Henderson K, Ichtchenko K, Brown MS, Goldstein JL, Deisenhofer J: Structure of the LDL receptor extracellular domain at endosomal pH. Science (2002) 298(5602):2353-2358. (Pubitemid 36014201)
33. Willnow TE, Rohlmann A, Horton J, Otani H, Braun JR, Hammer RE, Herz J: RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J (1996) 15(11):2632-2639. (Pubitemid 26176241)
34. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA: PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun (2008) 375(1):69-73.
35. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH: Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem (2007) 282(25):18602-18612. (Pubitemid 47100234)
36. Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, Tarachandani A et al: Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem (2007) 282(28):20502-20512. (Pubitemid 47100016)
37. Qian YW, Schmidt RJ, Zhang Y, Chu S, Lin A, Wang H, Wang X, Beyer TP, Bensch WR, Li W, Ehsani ME et al: Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res (2007) 48(7): 1488-1498. (Pubitemid 47312011)
38. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD: Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest (2006) 116(11):2995-3005. (Pubitemid 44684484)
39. Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z, Di Y et al: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA (2009) 106(24):9820-9825. •• Demonstrates antibody neutralization of PCSK9 is possible and proves that the primary mode of action of PCSK9 in degrading LDLR is as a secreted protein.
40. Fasano T, Sun XM, Patel DD, Soutar AK: Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis (2009) 203(1):166-171.
41. Holla ØL, Cameron J, Berge KE, Ranheim T, Leren TP: Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol (2007) 8:9.
42. Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A, Seidah NG: The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic (2007) 8(6):718-732. (Pubitemid 46785153)
43. Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH: Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci USA (2008) 105(35):13045-13050. • Presents data suggesting a function for the CRD of PCSK9 in mediating LDLR degradation, but not binding.
44. Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M: Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem (2006) 281(10):6211-6218. (Pubitemid 43847551)
45. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW: Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res (2008) 49(2):399-409. (Pubitemid 351213625)
46. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A: Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2004) 24(8):1454-1459. (Pubitemid 39050440)
47. Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ: Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem (2007) 53(10):1814-1819. (Pubitemid 47509675)
48. Lambert G, Ancellin N, Charlton F, Comas D, Pilot J, Keech A, Patel S, Sullivan DR, Cohn JS, Rye KA, Barter PJ: Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem (2008) 54(6):1038-1045. (Pubitemid 351793411)
49. Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chrétien M: Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis (2008) 7:22. (Pubitemid 351862290)
50. Mayne J, Raymond A, Chaplin A, Cousins M, Kaefer N, Gyamera-Acheampong C, Seidah NG, Mbikay M, Chrétien M, Ooi TC: Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun (2007) 361(2):451-456. (Pubitemid 47193117)
51. Fan D, Yancey PG, Qiu S, Ding L, Weeber EJ, Linton MF, Fazio S: Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry (2008) 47(6): 1631-1639. (Pubitemid 351231213)
52. Mayer G, Poirier S, Seidah NG: Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem (2008) 283(46):31791-31801.
53. Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zaïr Y, Nguyen P, Krempf M, Cariou B, Costet P: Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem (2008) 283(15):9666-9673.
54. Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE: Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis (2008) 201(2):266-273.
55. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S et al: Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med (2004) 10(12):1344-1351. (Pubitemid 40022716)
56. Cicero AF, Rovati LC, Setnikar I: Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung (2007) 57(1):26-30.
57. Kong WJ, Wei J, Zuo ZY, Wang YM, Song DQ, You XF, Zhao LX, Pan HN, Jiang JD: Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism (2008) 57(8):1029-1037. (Pubitemid 351978060)
58. Li H, Chen W, Zhou Y, Abidi P, Sharpe O, Robinson WH, Kraemer FB, Liu J: Identification of mRNA binding proteins that regulate the stability of LDL receptor mRNA through AU-rich elements. J Lipid Res (2009) 50(5):820-831.
59. Lambert G, Jarnoux AL, Pineau T, Pape O, Chetiveaux M, Laboisse C, Krempf M, Costet P: Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology (2006) 147(10): 4985-4995. (Pubitemid 44402206)
60. Langhi C, Le May C, Kourimate S, Caron S, Staels B, Krempf M, Costet P, Cariou B: Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett (2008) 582(6):949-955.
61. Nilsson LM, Abrahamsson A, Sahlin S, Gustafsson U, Angelin B, Parini P, Einarsson C: Bile acids and lipoprotein metabolism: Effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem Biophys Res Commun (2007) 357(3):707-711. (Pubitemid 46653837)
62. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM: Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res (2007) 48(4): 763-767. • Along with reference [63], provides evidence for the first true 'therapeutic' that targets PCSK9.
63. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, Gamba-Vitalo C et al: Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA (2008) 105(33):11915-11920. • Along with reference [62], provides evidence for the first true 'therapeutic' targeting PCSK9.
64. Kourimate S, Chétiveaux M, Jarnoux AL, Lalanne F, Costet P: Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes. Atherosclerosis (2009):doi:10.1016/j.atherosclerosis. 2009.02.012.
65. Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM: Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J (2009) 419(3):577-584.
66. Bottomley MJ, Cirillo A, Orsatti L, Ruggeri L, Fisher TS, Santoro JC, Cummings RT, Cubbon RM, Lo Surdo P, Calzetta A, Noto A et al: Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem (2009) 284(2):1313-1323.
67. McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, Lagace TA: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 284(16):10561-10570.
68. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH: Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab (2009) 94(7):2537-2543.
69. Sitlani A: Targeting PCSK9 for LDL-cholesterol lowering: A drug discovery challenge. Kern Aspen Lipid Conference, Aspen, CO, USA (2008).
70. Pandit S, Wisniewski D, Santoro JC, Ha S, Ramakrishnan V, Cubbon RM, Cummings RT, Wright SD, Sparrow CP, Sitlani A, Fisher TS: Functional analysis of sites within PCSK9 responsible for hypercholesterolemia. J Lipid Res (2008) 46(6):1333-1343.
71. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG: The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and apoER2. J Biol Chem (2008) 283(4):2363-2372.
72. Labonte P, Begley S, Guevin C, Asselin MC, Nassoury N, Mayer G,. Prat A, Seidah NG: PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology (2009) 50(1):17-24.
73. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S: Binding of hepatitis C virus to CD81. Science (1998) 282(5390):938-941.
74. Burlone ME, Budkowska A: Hepatitis C virus cell entry: Role of lipoproteins and cellular receptors. J Gen Virol (2009) 90(Pt 5):1055-1070.
75. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG et al: Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology (2008) 48(2): 646-654.
76. Jonas MC, Costantini C, Puglielli L: PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep (2008) 9(9):916-922.
77. Mbikay M, Mayne J, Seidah NG, Chrétien M: Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms. Med Hypotheses (2007) 69(5):1010-1017. (Pubitemid 47430234)